Primary Efficacy Endpoint and Safety Results of Ibalizumab in a Phase 3 Study of Heavily Treatment-Experienced Patients With Multidrug-Resistant Human Immunodeficiency Virus-1 Infection

Multidrug Resistant ◽

Primary Efficacy ◽

Primary Efficacy Endpoint ◽

Phase 3 ◽

Immunodeficiency Virus ◽

1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1–6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials

Open Forum Infectious Diseases ◽

10.1093/ofid/ofy210.1621 ◽

2018 ◽

Vol 5 (suppl_1) ◽

pp. S569-S570

Author(s):

Jurgen K Rockstroh ◽

Sanjay R Bhagani ◽

Chloe Orkin ◽

Ruth Soto-Malave ◽

Karine Lacombe ◽

...

Keyword(s):

Integrated Analysis ◽

Phase 3 ◽

Two Phase ◽

Safety And Efficacy ◽

Immunodeficiency Virus ◽

Chronic Hepatitis C Virus ◽

Virus Genotypes ◽

Hepatitis C Virus Genotypes ◽

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice ◽

10.1080/15284336.2019.1589232 ◽

2019 ◽

Vol 20 (3) ◽

pp. 73-81 ◽

Cited By ~ 2

Author(s):

Yeon-Sook Kim ◽

Shinichi Oka ◽

Ploenchan Chetchotisakd ◽

Amanda Clarke ◽

Khuanchai Supparatpinyo ◽

...

Keyword(s):

Clinical Trials ◽

Efficacy And Safety ◽

Phase 3 ◽

Immunodeficiency Virus ◽

Tenofovir Alafenamide ◽

N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of nni-resistant and multidrug-resistant human immunodeficiency virus-1

Bioorganic & Medicinal Chemistry Letters ◽

10.1016/s0960-894x(99)00624-1 ◽

1999 ◽

Vol 9 (24) ◽

pp. 3411-3416 ◽

Cited By ~ 39

Author(s):

Fatih M. Uckun ◽

Sharon Pendergrass ◽

Danielle Maher ◽

Dan Zhu ◽

Lisa Tuel-Ahlgren ◽

...

Keyword(s):

Potent Inhibitor ◽

Multidrug Resistant ◽

Immunodeficiency Virus ◽

Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study

Chinese Medical Journal ◽

10.1097/cm9.0000000000001273 ◽

2020 ◽

Vol 133 (24) ◽

pp. 2919-2927

Author(s):

Bin Su ◽

Cheng Yao ◽

Qing-Xia Zhao ◽

Wei-Ping Cai ◽

Min Wang ◽

...

Keyword(s):

Interim Analysis ◽

Fusion Inhibitor ◽

Efficacy And Safety ◽

Phase 3 ◽

Randomized Controlled ◽

Immunodeficiency Virus ◽

Long Acting ◽

N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]- thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1

Bioorganic & Medicinal Chemistry Letters ◽

10.1016/s0960-894x(99)00460-6 ◽

1999 ◽

Vol 9 (18) ◽

pp. 2721-2726 ◽

Cited By ~ 36

Author(s):

Fatih M. Uckun ◽

Chen Mao ◽

Sharon Pendergrass ◽

Danielle Maher ◽

Dan Zhu ◽

...

Keyword(s):

Multidrug Resistant ◽

Immunodeficiency Virus ◽

ChemInform Abstract: N-[2-(1-Cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-Cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus-1.

ChemInform ◽

10.1002/chin.199952147 ◽

2010 ◽

Vol 30 (52) ◽

pp. no-no

Author(s):

Fatih M. Uckun ◽

Chen Mao ◽

Sharon Pendergrass ◽

Danielle Maher ◽

Dan Zhu ◽

...

Keyword(s):

Multidrug Resistant ◽

Immunodeficiency Virus ◽

ChemInform Abstract: N′-[2-(2-Thiophene)ethyl]-N′-[2′-(5-bromopyridyl)]-thiourea as a Potent Inhibitor of NNI-Resistant and Multidrug-Resistant Human Immunodeficiency Virus-1.

ChemInform ◽

10.1002/chin.200012146 ◽

2010 ◽

Vol 31 (12) ◽

pp. no-no

Author(s):

Fatih M. Uckun ◽

Sharon Pendergrass ◽

Danielle Maher ◽

Dan Zhu ◽

Lisa Tuel-Ahlgren ◽

...

Keyword(s):

Potent Inhibitor ◽

Multidrug Resistant ◽

Immunodeficiency Virus ◽

Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials

Infection and Chemotherapy ◽

10.3947/ic.2016.48.3.219 ◽

2016 ◽

Vol 48 (3) ◽

pp. 219 ◽

Cited By ~ 1

Author(s):

Jun Yong Choi ◽

Somnuek Sungkanuparph ◽

Thanomsak Anekthananon ◽

Paul Sax ◽

Edwin DeJesus ◽

...

Keyword(s):

Clinical Trials ◽

Tenofovir Disoproxil Fumarate ◽

Efficacy And Safety ◽

Phase 3 ◽

Immunodeficiency Virus ◽

Workflow Optimization of the ViroSeqTM Human Immunodeficiency Virus-1 (HIV-1) Genotyping System

Journal of Human Virology & Retrovirology ◽

10.15406/jhvrv.2015.02.00071 ◽

2015 ◽

Vol 2 (7) ◽

Author(s):

Danijela Lucic

Keyword(s):

Workflow Optimization ◽

Immunodeficiency Virus ◽

Hiv 1 ◽

Faculty Opinions recommendation of Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1015392.196706 ◽

2003 ◽

Author(s):

Luis J Montaner

Keyword(s):

Treatment Interruption ◽

Multidrug Resistant ◽

Immunodeficiency Virus